Metabolic syndrome common with chronic hep B infection

Metabolic syndrome common with chronic hep B infection

(HealthDay)—Metabolic syndrome (MetS) is prevalent among patients with chronic hepatitis B (HBV) infection, according to a study published online March 29 in Diabetes Care.

Mandana Khalili, M.D., from the University of California, San Francisco, and colleagues assessed prevalence of MetS and its influence on alanine aminotransferase (ALT) levels and fibrosis among a multiethnic North American cohort with chronic HBV infection (777 patients).

The researchers found that 22 percent of patients with chronic HBV had MetS. MetS was associated with age ( 54.4, versus 40.2 years without MetS) and sex (61 percent male). At baseline, MetS was not associated with ALT or aspartate aminotransferase-to-platelet ratio index (APRI). However, ALT was significantly higher (P = 0.02) among those with MetS at baseline, and even higher (P = 0.003) among those with persistent MetS in adjusted multivariable analysis of serial ALT values. At follow-up, MetS was not associated with serial APRI.

"MetS was prevalent in this HBV cohort and was independently associated with higher ALT levels longitudinally," the authors write. "These findings highlight the importance of screening for MetS and the potential for MetS to influence ALT and its interpretation in the context of HBV treatment decisions."

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)

Journal information: Diabetes Care

Copyright © 2018 HealthDay. All rights reserved.

Citation: Metabolic syndrome common with chronic hep B infection (2018, April 17) retrieved 7 May 2024 from https://medicalxpress.com/news/2018-04-metabolic-syndrome-common-chronic-hep.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Chemo ups metabolic syndrome risk in early-stage breast cancer

5 shares

Feedback to editors